You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

high-risk B-cell malignancies

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Leukemia, Lymphoma, Lymphoma, B-Cell Trial in New York (CAR T-Cell Infusion)

Withdrawn
  • Leukemia
  • +2 more
  • CAR T-Cell Infusion
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 4, 2022

Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome Trial (VIP943)

Not yet recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • (no location specified)
Sep 5, 2023

Leukemia, Myelodysplastic Syndrome, Lymphoma Trial in New York (CliniMACS Fractionation system (Arm A), CliniMACS Fractionation

Completed
Has Results
  • Leukemia
  • +2 more
  • CliniMACS Fractionation system (Arm A)
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 12, 2022

Cell-free DNA in Hereditary And High-Risk Malignancies

Recruiting
  • Hereditary Cancer Syndrome
  • Next generation sequencing (NGS)
  • Vancouver, British Columbia, Canada
  • +6 more
Feb 14, 2022

Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Minneapolis (HSCT with TBI Regimen, HSCT with

Recruiting
  • Acute Leukemia
  • +27 more
  • HSCT with TBI Regimen
  • HSCT with Non-TBI Regimen
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Apr 12, 2022

Acute Lymphocytic Leukemia, Lymphoma Trial in New York (Biological/Genetically Modified T cells, Cyclophosphamide-based chemo)

Active, not recruiting
  • Acute Lymphocytic Leukemia
  • Lymphoma
  • Biological/Genetically Modified T cells
  • Cyclophosphamide-based chemotherapy
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 3, 2023

Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma Trial in Dresden (MDC-CAR-BCMA001 (BCMA directed CAR

Not yet recruiting
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma
  • MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
  • Dresden, Germany
    Technische Universität Dresden, NCT/UCC, Early Clinical Trial Un
Apr 19, 2023

Hypomethylating Agent, Venetoclax, Myeloid Malignancy Trial in Shanghai (Venetoclax, Azacitidine or decitabine)

Recruiting
  • Hypomethylating Agent
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Jiao Tong University School of Medicine Affilated Shang
May 2, 2023

Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in

Completed
  • Relapsed or Refractory Haematological Malignancies Including
  • +10 more
  • Aachen, Germany
  • +11 more
Oct 21, 2021

Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present, DLBCL Trial in Seattle (biological, procedure, drug, radiation, other)

Terminated
Has Results
  • Burkitt Lymphoma
  • +6 more
  • Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein
  • +11 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 30, 2020

Frontline of ASCT in High-risk DLBCL

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Beijing, Beijing, China
      Peking University People's Hospital
    Apr 26, 2023

    "Don't Eat me" Signal in Hematological Malignancies: CD24 as New

    Recruiting
    • Mantle-cell Lymphoma
    • B Cell Chronic Lymphocytic Leukemia
      • Monza, MB, Italy
        Andrea Aroldi
      May 24, 2023

      Multiple Myeloma (MM), DLBCL, Not Otherwise Specified, Double Hit Lymphoma Trial in Spain (IDP-121)

      Recruiting
      • Multiple Myeloma (MM)
      • +5 more
      • Santander, Cantabria, Spain
      • +4 more
      Jun 19, 2023

      Hematologic Tumors Trial run by the NCI (donor lymphocyte infusion, Cyclophosphamide, Busulfan)

      Suspended
      • Hematologic Neoplasms
      • donor lymphocyte infusion
      • +5 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Nov 30, 2022

      Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

      Recruiting
      • Follicular Lymphoma
      • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 20, 2023

      Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Tampa (Comprehensive Ablative Bridging Irradiation (CABI),

      Recruiting
      • Large B-cell Lymphoma
      • Relapsed Non-Hodgkin Lymphoma
      • Comprehensive Ablative Bridging Irradiation (CABI)
      • Chimeric Antigen Receptor T-Cell Therapy
      • Tampa, Florida
        Moffitt Cancer Center
      Oct 26, 2023

      Diffuse Large B-cell Lymphoma Trial in Changchun (Mitoxantrone HCl liposome injection, RiTUXimab Injection, Cyclophosphamid)

      Not yet recruiting
      • Diffuse Large B-cell Lymphoma
      • Mitoxantrone hydrochloride liposome injection
      • +4 more
      • Changchun, Jilin, China
        The First Bethune Hospital of Jilin University
      Aug 15, 2023

      CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

      Not yet recruiting
      • CD19-positive Relapsed or Refractory B-cell Malignancies
      • UTAA09 cells for infusion
      • +2 more
      • Hefei, Anhui, China
        The First Affiliated Hospital of USTC (AnHui Provincial Hospital
      Oct 13, 2023

      Leukemia, Myeloid, Acute, MDS, Hematopoietic Stem Cell Transplantation Trial in Shanghai (Venetoclax plus RIC)

      Not yet recruiting
      • Leukemia, Myeloid, Acute
      • +3 more
      • Venetoclax plus RIC
      • Shanghai, Shanghai, China
        Shanghai General Hospital
      Oct 12, 2022

      Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)

      Not yet recruiting
      • Non Hodgkin Lymphoma
      • +5 more
      • (no location specified)
      Aug 4, 2023

      B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)

      Recruiting
      • B Cell Malignancies
      • Universal CD19-specific CAR gene-engineered T cells
      • Beijing, Beijing, China
      • +2 more
      Aug 8, 2023

      B-cell Malignancies Undergoing Treatment With Bruton Tyrosine

      Not yet recruiting
      • Chronic Lymphocytic Leukemia
      • +4 more
      • Non-Interventional Study
      • Rochester, Minnesota
        Mayo Clinic in Rochester
      Nov 22, 2023

      B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors Trial in Kunming (Anti-CD19 Autologous CAR-T Cell Infusion)

      Recruiting
      • B-Cell Leukemia
      • +2 more
      • Anti-CD19 Autologous CAR-T Cell Infusion
      • Kunming, Yunnan, China
        920th Hospital of Joint Logistics Support Force of People's Libe
      Jul 9, 2023

      Diffuse Large B Cell Lymphoma Trial in Shenyang (Zanubrutinib, Rituximab, Cyclophosphamide)

      Not yet recruiting
      • Diffuse Large B Cell Lymphoma
      • Shenyang, Liaoning, China
        Xing Xiaojing
      Jun 1, 2023

      Lymphoma, Lymphoma, Large B-Cell, Diffuse Trial in Boston (Glofitamab, Polatuzumab, Rituximab)

      Not yet recruiting
      • Lymphoma
      • Lymphoma, Large B-Cell, Diffuse
      • Boston, Massachusetts
      • +1 more
      Apr 4, 2023